Indivior (NASDAQ:INDV) Cut to Buy at Wall Street Zen

Wall Street Zen lowered shares of Indivior (NASDAQ:INDV) from a strong-buy rating to a buy rating in a research report released on Saturday,Wall Street Zen reports.

INDV has been the subject of several other reports. Barclays increased their price objective on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $53.00 target price on shares of Indivior in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $46.40.

Indivior Stock Up 2.6%

Shares of NASDAQ:INDV opened at $36.28 on Friday. The business has a 50 day moving average price of $35.18 and a 200 day moving average price of $35.63. Indivior has a twelve month low of $27.68 and a twelve month high of $42.81. The company has a market cap of $4.28 billion, a price-to-earnings ratio of 9.53 and a beta of 0.87.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.26. The firm had revenue of $356.00 million for the quarter, compared to analyst estimates of $329.35 million. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. Analysts anticipate that Indivior will post 3.66 EPS for the current year.

Indivior Announces Dividend

The business also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be paid a $8.13 dividend.

Insiders Place Their Bets

In other news, CAO Woodrow D. Anderson bought 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average cost of $35.69 per share, with a total value of $53,535.00. Following the completion of the transaction, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. This represents a 5.74% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.74% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Indivior

Several large investors have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. grew its holdings in shares of Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after purchasing an additional 1,076 shares in the last quarter. TD Waterhouse Canada Inc. bought a new stake in shares of Indivior during the second quarter valued at approximately $63,000. GAMMA Investing LLC bought a new stake in shares of Indivior during the second quarter valued at approximately $66,000. Farther Finance Advisors LLC raised its stake in shares of Indivior by 716.2% in the third quarter. Farther Finance Advisors LLC now owns 3,624 shares of the company’s stock valued at $130,000 after purchasing an additional 3,180 shares in the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of Indivior by 482.1% in the third quarter. Sterling Capital Management LLC now owns 3,772 shares of the company’s stock valued at $135,000 after purchasing an additional 3,124 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.